In a 500-patient phase 3 trial, daraxonrasib extends median overall survival to 13.2 vs 6.7 months for chemotherapy in second-line metastatic pancreatic cancer.
$18 of Stored Value on every ticket to be used for food purchase at concession stands throughout ballpark.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results